PH21673A - Solid drug formulations and stable suspensions - Google Patents

Solid drug formulations and stable suspensions

Info

Publication number
PH21673A
PH21673A PH33012A PH33012A PH21673A PH 21673 A PH21673 A PH 21673A PH 33012 A PH33012 A PH 33012A PH 33012 A PH33012 A PH 33012A PH 21673 A PH21673 A PH 21673A
Authority
PH
Philippines
Prior art keywords
stable suspensions
solid drug
drug formulations
suspensions
stable
Prior art date
Application number
PH33012A
Other languages
English (en)
Inventor
Leo Geller
Peter Glanzmann
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PH21673A publication Critical patent/PH21673A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Drying Of Solid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Magnetic Record Carriers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
PH33012A 1984-11-06 1985-11-05 Solid drug formulations and stable suspensions PH21673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH530584 1984-11-06

Publications (1)

Publication Number Publication Date
PH21673A true PH21673A (en) 1988-01-13

Family

ID=4291364

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33012A PH21673A (en) 1984-11-06 1985-11-05 Solid drug formulations and stable suspensions

Country Status (26)

Country Link
US (1) US5002940A (da)
EP (2) EP0346953B1 (da)
JP (2) JPS61204118A (da)
KR (1) KR890000907B1 (da)
AT (2) ATE51152T1 (da)
AU (2) AU586988B2 (da)
CA (1) CA1249223A (da)
CY (2) CY1898A (da)
DD (1) DD244292A5 (da)
DE (2) DE3576650D1 (da)
DK (1) DK162510C (da)
ES (1) ES8701491A1 (da)
FI (1) FI85809C (da)
GR (1) GR852637B (da)
HK (2) HK101192A (da)
HU (1) HU195728B (da)
IE (2) IE63166B1 (da)
IL (1) IL76943A (da)
MX (1) MX9203371A (da)
NL (1) NL940015I2 (da)
NO (1) NO169324C (da)
NZ (2) NZ229276A (da)
PH (1) PH21673A (da)
PT (1) PT81429B (da)
SG (1) SG107192G (da)
ZA (1) ZA858481B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH673395A5 (da) * 1987-01-30 1990-03-15 Ciba Geigy Ag
MX9201782A (es) * 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
CA2352178A1 (en) * 1998-12-08 2000-06-15 Mathew Louis Steven Leigh Phospholipid compositions
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6487907B1 (en) * 1999-07-08 2002-12-03 California Institute Of Technology Microgyroscope with integrated vibratory element
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
WO2019213286A1 (en) * 2018-05-02 2019-11-07 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2068447A1 (en) * 1969-11-26 1971-08-27 Orsymonde Dehydrated pharmaceutical comps by - lyophilisation
LU77457A1 (da) * 1977-05-31 1979-01-19
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
JPS58206513A (ja) * 1982-05-28 1983-12-01 Eisai Co Ltd セクレチン吸着防止組成物および方法
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
DE3339295A1 (de) * 1982-11-15 1984-05-17 Schering AG, 1000 Berlin und 4709 Bergkamen 4-hydroxy- und 4-acyloxy-4-androsten-3,17-dione zur verwendung bei der prophylaxe und therapie der prostatahyperplasie und diese enthaltende mittel fuer derartige verwendung
EP0117811A3 (fr) * 1983-02-23 1987-06-03 Sanofi S.A. Compositions pharmaceutiques antifongiques utilisables par voie orale
EP0226021A1 (de) * 1985-12-12 1987-06-24 BBC Brown Boveri AG Thyristor mit schaltbarem Emitter-Kurzschluss

Also Published As

Publication number Publication date
CA1249223A (en) 1989-01-24
EP0346953A2 (de) 1989-12-20
KR890000907B1 (ko) 1989-04-13
IE63156B1 (en) 1995-03-22
DE3587020D1 (de) 1993-03-04
NO854403L (no) 1986-05-07
ZA858481B (en) 1986-06-25
ATE51152T1 (de) 1990-04-15
AU586988B2 (en) 1989-08-03
FI854330A (fi) 1986-05-07
NO169324B (no) 1992-03-02
ES548492A0 (es) 1986-12-01
DD244292A5 (de) 1987-04-01
EP0181287B1 (de) 1990-03-21
IL76943A (en) 1990-02-09
FI854330A0 (fi) 1985-11-04
DK162510C (da) 1992-03-30
FI85809B (fi) 1992-02-28
GR852637B (da) 1986-03-04
US5002940A (en) 1991-03-26
FI85809C (fi) 1992-06-10
IE63166B1 (en) 1995-03-22
NL940015I1 (nl) 1994-10-17
HK101192A (en) 1992-12-24
DK162510B (da) 1991-11-11
AU4934485A (en) 1986-05-15
JPH0768130B2 (ja) 1995-07-26
EP0346953B1 (de) 1993-01-20
EP0346953A3 (en) 1990-11-22
AU633844B2 (en) 1993-02-11
JPH0648945A (ja) 1994-02-22
IE852755L (en) 1986-05-06
PT81429A (en) 1985-12-01
NZ229276A (en) 1989-08-29
ATE84718T1 (de) 1993-02-15
HK192095A (en) 1995-12-29
DK509485A (da) 1986-05-07
HU195728B (en) 1988-07-28
PT81429B (pt) 1988-03-03
JPH0558410B2 (da) 1993-08-26
CY1677A (en) 1993-10-10
IE902490L (en) 1986-05-06
MX9203371A (es) 1992-09-01
NZ214069A (en) 1989-08-29
DK509485D0 (da) 1985-11-05
ES8701491A1 (es) 1986-12-01
CY1898A (en) 1985-10-31
NL940015I2 (nl) 1997-01-06
EP0181287A2 (de) 1986-05-14
DE3576650D1 (de) 1990-04-26
JPS61204118A (ja) 1986-09-10
SG107192G (en) 1992-12-24
HUT42936A (en) 1987-09-28
KR860003825A (ko) 1986-06-13
EP0181287A3 (en) 1987-09-23
AU4150489A (en) 1990-01-04
NO169324C (no) 1992-06-10

Similar Documents

Publication Publication Date Title
ES537578A0 (es) Procedimiento para la estabilizacion de preparados farmaceuticos en forma de suspensiones conteniendo sucralfato
HK160895A (en) Complexes of saponins with phospholipids and pharmaceutical and cosmetic compositions containing them
PH21673A (en) Solid drug formulations and stable suspensions
IL83318A0 (en) 1,4-benzodiazepines,their preparation and pharmaceutical compositions containing them
IL75485A0 (en) Ethanolamine compounds,their preparation and pharmaceutical compositions containing them
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
MY8500617A (en) Phenantrene derivatives, their preparation and pharmaceutical compositions containing them
IL57077A0 (en) 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them